For most of the twentieth century, a person with narcolepsy or crushing daytime sleepiness had two pharmacological options: amphetamines or methylphenidate. Both worked, and both carried the baggage of classic stimulants. The arrival of modafinil in the late 1990s created a new category, the eugeroic or wakefulness-promoting agent, and since then the field has grown to include armodafinil, solriamfetol, and pitolisant. Each has a different mechanism, a different pharmacokinetic profile, and a different regulatory status. This guide lays the four side by side so you can understand what actually separates them.
The category in brief
A wakefulness-promoting agent is a drug that increases alertness and reduces sleep propensity without the broad sympathetic activation that amphetamines produce. The practical markers are a lack of euphoria at therapeutic doses, minimal effect on rebound hypersomnia, relatively little cardiovascular stimulation, and low abuse liability. None of the four drugs below are perfectly clean on every count, but all sit well apart from the traditional stimulants.
The oldest of the group, modafinil, remains the reference point. It is the most widely used, the best studied, the most commonly prescribed off-label, and the one people usually mean when they mention a wakefulness-promoting agent in everyday conversation. Its cousin adrafinil, a prodrug converted to modafinil in the liver, is now obsolete and is mentioned here only for completeness.
Modafinil
Mechanism. Modafinil binds the dopamine transporter (DAT) and blocks dopamine reuptake, producing a modest rise in extracellular dopamine in the striatum and prefrontal cortex. Its effect on norepinephrine reuptake is weaker. Downstream, it increases orexin and histamine signaling in wake-promoting circuits and reduces GABA release in some regions. The DAT effect is now considered essential, since animals lacking the transporter do not respond, but the drug is far less potent at DAT than cocaine or amphetamine and does not trigger dopamine release.
Pharmacokinetics. Oral bioavailability is good; peak concentrations arrive two to four hours after dosing; half-life is about 12 to 15 hours. It is metabolized primarily in the liver and induces CYP3A4 while inhibiting CYP2C19.
Approved uses. Narcolepsy, obstructive sleep apnea with residual sleepiness despite treatment, and shift work disorder. Typical dosing is 200 mg once in the morning, with a range of 100 to 400 mg.
Profile. Headache, nausea, nervousness, and insomnia are the main complaints. Rare severe skin reactions have been reported. It reduces the effectiveness of hormonal contraception. In the US it is Schedule IV.
Armodafinil
Mechanism. Identical to modafinil, because it is modafinil. Racemic modafinil is a 50:50 mix of R- and S-enantiomers; armodafinil is the purified R-form, which is the more active and longer-lasting of the two.
Pharmacokinetics. Because the S-isomer clears in roughly three to four hours while the R-isomer persists for around 15, armodafinil maintains higher concentrations late in the day for a given milligram dose. Peak is again around two hours, but the curve is flatter and longer.
Approved uses. The same three indications. Standard doses are 150 to 250 mg once daily; 150 mg is the usual starting point.
Profile. Side-effect pattern mirrors modafinil, with a slightly higher reported rate of headache in some comparisons, possibly because of the sustained exposure. Also Schedule IV.
Where it fits. Armodafinil is best thought of as a formulation choice rather than a distinct drug. People who need late-afternoon coverage may prefer it; people who struggle with insomnia may prefer modafinil’s earlier fade.
Solriamfetol
Mechanism. Solriamfetol is a dual dopamine and norepinephrine reuptake inhibitor with roughly balanced affinity for the two transporters. That makes it closer in principle to bupropion or atomoxetine than to modafinil, though it is considerably more potent at promoting wakefulness. It does not release monoamines the way amphetamine does.
Pharmacokinetics. Rapid absorption, peak around two hours, half-life around seven hours, and it is largely excreted unchanged in urine. Because it is renally cleared, doses must be reduced in kidney impairment. It does not significantly induce or inhibit the major liver enzymes, which simplifies drug interactions.
Approved uses. Approved in 2019 for excessive daytime sleepiness in narcolepsy (75 to 150 mg) and in obstructive sleep apnea (37.5 to 150 mg). Not approved for shift work disorder.
Profile. Because of the norepinephrine component, it raises blood pressure and heart rate more noticeably than modafinil. Headache, decreased appetite, anxiety, and insomnia are common. It is contraindicated with MAO inhibitors. Also Schedule IV.
Where it fits. Solriamfetol is often used when modafinil fails or is not tolerated, and some trials suggest it produces larger improvements on objective wakefulness testing at the top dose. The trade-off is cardiovascular.
Pitolisant
Mechanism. Pitolisant is the odd one out. It is a histamine H3 receptor inverse agonist and antagonist. H3 receptors act as autoreceptors that suppress histamine release; blocking them increases histamine output from the tuberomammillary nucleus, one of the brain’s key wake-promoting centers. It has no meaningful action at dopamine transporters and does not raise dopamine in reward circuits.
Pharmacokinetics. Peak in about three hours, half-life around 10 to 12 hours, with extensive liver metabolism through CYP2D6 and CYP3A4. Genetic poor metabolizers at CYP2D6 need lower doses.
Approved uses. Approved for excessive daytime sleepiness in narcolepsy and, notably, for cataplexy as well, which modafinil does not treat. Doses are titrated over weeks from 8.9 mg up to 35.6 mg once daily.
Profile. Insomnia, headache, nausea, and anxiety are the main effects. It can prolong the QT interval, so ECG monitoring is sometimes advised. Crucially, it is not a controlled substance in the US, because the DEA review found no evidence of abuse potential.
Where it fits. Pitolisant is attractive when abuse liability must be zero, when cataplexy is a problem, or when a patient cannot tolerate any dopaminergic drug. It is slower to reach full effect, typically requiring several weeks.
Side-by-side comparison
| Feature | Modafinil | Armodafinil | Solriamfetol | Pitolisant |
| Primary mechanism | DAT inhibition | DAT inhibition (R-isomer) | DAT + NET inhibition | H3 inverse agonist |
| Half-life | 12 to 15 h | ~15 h | ~7 h | 10 to 12 h |
| Onset of effect | 1 to 2 h | 1 to 2 h | ~1 h | Weeks to full effect |
| Typical dose | 100 to 200 mg | 150 to 250 mg | 75 to 150 mg | 8.9 to 35.6 mg |
| Shift work approval | Yes | Yes | No | No |
| Treats cataplexy | No | No | No | Yes |
| US schedule | IV | IV | IV | Unscheduled |
| Main concern | Skin reactions, drug interactions | Same as modafinil | Blood pressure | QT interval, slow titration |
How to read the table
The two modafinil products dominate on breadth of approvals and cost, since generics are inexpensive. Solriamfetol trades cardiovascular tolerability for a somewhat stronger wake signal in head-to-head-ish comparisons. Pitolisant trades speed for a unique safety and regulatory profile.
Choosing between them in practice
Clinicians typically start with modafinil because of familiarity, price, and forty years of accumulated safety data. Reasons to move to another option include:
- Inadequate response at 400 mg, which pushes toward solriamfetol or a traditional stimulant.
- Intolerable headaches or anxiety, which sometimes resolve on pitolisant.
- Hormonal contraception or other CYP3A4-dependent medications, where solriamfetol’s lack of enzyme effects helps.
- Cataplexy, which argues strongly for pitolisant or sodium oxybate.
- A history of substance use disorder, where an unscheduled drug is preferable.
- Hypertension or arrhythmia, which argues against solriamfetol and for careful ECG review with pitolisant.
Research suggests that combining a low dose of two agents with different mechanisms, such as modafinil with pitolisant, can sometimes achieve alertness that neither reaches alone, though this is specialist territory.
A note on off-label and non-clinical use
Modafinil is by far the most common of the four to be used by healthy people seeking better concentration, and it is the only one with a large body of research in non-sleep-deprived volunteers. Those studies show modest improvements in attention and some executive functions, larger benefits under sleep deprivation, and no meaningful gain on simple memory tasks. The newer agents have essentially no data in healthy users, and their side-effect profiles make them poor candidates for that purpose. Anyone considering a cognitive enhancer of this type should know that prescription rules differ widely by country, that a doctor should review interactions and cardiovascular risk first, and that none of these drugs substitutes for sleep.
FAQ
Is armodafinil twice as strong as modafinil? No. Milligram for milligram it is somewhat more potent because the inactive S-isomer is removed, but 150 mg armodafinil is roughly comparable to 200 mg modafinil in overall exposure.
Which one works fastest? Solriamfetol tends to be felt within the first hour, modafinil and armodafinil within one to two hours. Pitolisant is a slow-build drug measured in weeks.
Which has the lowest abuse potential? Pitolisant, which is not scheduled at all. The other three are Schedule IV, which is the second-lowest tier of controlled substances.
Can any of them be used for shift work? Only modafinil and armodafinil carry that approval. Solriamfetol’s shorter half-life has drawn interest, but it has not been formally studied for it.
Do they treat the underlying cause of sleepiness? No. All four manage the symptom. Sleep apnea still needs CPAP, narcolepsy remains a lifelong condition, and shift work still disrupts the clock.
Final Thoughts
The four modern eugeroics represent three distinct strategies for pushing the brain toward wakefulness: raising dopamine tone gently, raising dopamine and norepinephrine together, or raising histamine. Modafinil and armodafinil remain the default because they balance effectiveness, tolerability, and cost. Solriamfetol offers more power at the price of cardiovascular load, and pitolisant offers a clean regulatory profile and cataplexy control at the price of patience. Understanding those trade-offs, rather than treating them as interchangeable, is what allows a patient and physician to pick the one that fits.
For more topic guides and related resources, visit Modavance.
